CARLSBAD, Calif., Jan. 22,
2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, announced
today that two abstracts were accepted for presentation at the 2025
ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place
January 23-25, 2025, in San Francisco, CA.
Details of the poster presentations are below:
Title: "A multicenter, open-label, first-in-human
study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and
other solid tumors with activating FGFR2 gene
alterations (SURF201)"
Abstract: TPS646
Presenting Author: Robin Kate
Kelley, MD, University of California
San Francisco
Session: Trials in Progress Poster Session B: Cancers
of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 24, 2025, 11:30 AM – 1:00 PM
PST, Level 1, West Hall
Title: "TYRA-430: First reversible FGFR4/3 inhibitor
designed to overcome current challenges in FGF19-driven
hepatocellular carcinoma treatment"
Abstract: 583
Presenting Author: Ronald Swanson, Ph.D., Tyra
Biosciences
Session: Poster Session B: Cancers of the Pancreas,
Small Bowel, and Hepatobiliary Tract
Date/Time: January 24, 2025, 11:30 AM – 1:00 PM
PST, Level 1, West Hall
The abstracts related to these posters and additional
information can be found on the ASCO GI website.
About TYRA-200
TYRA-200 is an oral, investigational, FGFR1/2/3 inhibitor with
potency against activating FGFR2 gene alterations and resistance
mutations. The Phase 1 clinical study of TYRA-200, SURF201
(Study in PrevioUsly treated
and Resistant FGFR2+ Cholangiocarcinoma and
Other Advanced Solid Tumors) (NCT06160752), is a multi-center, open
label study designed to evaluate the maximum tolerated dose (MTD)
and the recommended Phase 2 dose of TYRA-200, as well as to
evaluate the preliminary antitumor activity of TYRA-200. SURF201 is
currently enrolling and dosing adults with advanced/metastatic
intrahepatic cholangiocarcinoma and other advanced solid tumors
with activating alterations in FGFR2.
About TYRA-430
TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor
for FGF19+/FGFR4-driven cancers. The US Food and Drug
Administration has cleared Tyra's Investigational New Drug
application to proceed with a Phase 1 clinical study of TYRA-430.
The Phase 1 study will be a multicenter, open-label, first-in-human
study of TYRA-430 in advanced hepatocellular carcinoma (HCC) and
other solid tumors with activating FGF/FGFR pathway aberrations
(SURF431).
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's expertise
in FGFR biology has created a differentiated pipeline with three
clinical-stage programs in targeted oncology and genetically
defined conditions. The Company's lead precision medicine stemming
from SNÅP, TYRA-300, is a potential first-in-class selective
FGFR3 inhibitor that is designed to avoid the toxicities associated
with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for
the FGFR3 gatekeeper mutations. TYRA-300 is expected to be
evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301
for pediatric achondroplasia and SURF301 for metastatic urothelial
cancer. TYRA is also developing TYRA-200, an oral, investigational,
FGFR1/2/3 inhibitor, in the SURF201 study for metastatic
intrahepatic cholangiocarcinoma, and TYRA-430, an oral,
investigational FGFR4/3-biased inhibitor for
FGF19+/FGFR4-driven cancers. TYRA is based in
Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on LinkedIn.
Forward-Looking Statements
TYRA cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to: the potential to develop next-generation precision
medicines and for TYRA-300 to be first-in-class, and the potential
safety and therapeutic benefits of our product candidates; the
expected timing and phase of development of TYRA-300; and the
potential for SNÅP to develop therapies in targeted oncology and
genetically defined conditions. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: later developments with the FDA may be inconsistent
with prior feedback from the FDA; we are early in our development
efforts, have only recently begun testing TYRA-300 and TYRA-200 for
oncology in clinical trials and the approach we are taking to
discover and develop drugs based on our SNÅP platform is novel and
unproven and it may never lead to product candidates that are
successful in clinical development or approved products of
commercial value; potential delays in the commencement, enrollment,
data readouts and completion of preclinical studies and clinical
trials; results from preclinical studies or early clinical trials
not necessarily being predictive of future results; interim results
of a clinical trial are not necessarily indicative of final results
and one or more of the clinical outcomes may materially change as
patient enrollment continues, following more comprehensive reviews
of the data, as follow-up on the outcome of any particular patient
continues and as more patient data becomes available, including the
risk that unconfirmed responses may not ultimately result in
confirmed responses to treatment after follow-up evaluations;
unexpected adverse side effects or inadequate efficacy of our
product candidates that may limit their development, regulatory
approval, and/or commercialization; and other risks described in
our prior filings with the Securities and Exchange
Commission (SEC), including under the heading "Risk Factors"
in our annual report on Form 10-K and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and we undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-poster-presentations-at-2025-asco-gastrointestinal-cancers-symposium-302357388.html
SOURCE Tyra Biosciences